Gastrointestinal Drugs Advisory Committee Meeting

Gastrointestinal Drugs Advisory Committee Meeting
Committee Meeting August 28, 2012 8:00 a.m. to 5:00 p.m.

Agenda: The committee will discuss the results from clinical trials of supplemental biologics license application (sBLA) 125057/232, for Humira (adalimumab), by Abbott Laboratories, for the proposed indication (use) for reducing signs and symptoms, and achieving clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.